Aviceda Therapeutics

Developer of biotherapeutics for glycol-immune diseases

placeCambridge, Massachusetts, United States calendar_todayFounded 2018 groups16 employees language avicedarx.com

Innovation

3 patent families — focus: Human necessities; filing pace accelerating. Cited 33 times.

YearFilings
20221
20232
20243
20252
20261

Social engagement

Social engagement: 6.4K social following, 3 posts in the last 12 months — below the industry typical range.

Investor mix

12 investors on record; lead investors include Omega Funds.

Investor typeCountShare
Venture capital650%
Private equity18%
Bank & private debt18%
Other / undisclosed433%

Recent activity

4 Sep 2025
Event
webinar
31 Jul 2025
Event
ASRS annual meeting at the Long Beach Convention Center
31 Jul 2025
Event
ASRS annual meeting at the Long Beach Convention Center
Coming soon